Abstract: A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.

Abstract: Methods for detecting an infection with Mycobacterium tuberculosis (Mtb) in a subject are disclosed. The methods include detecting the presence of CD8+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8+ T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods can also include detecting Mtb polypeptides and polynucleotides. Reagents for the detection of an Mtb infection are also disclosed.

Abstract: A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.

Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.

Abstract: Methods, articles of manufacture, and systems for evaluating tinnitus are disclosed herein. According to various embodiments, a tinnitus evaluation system may include a tinnitus evaluation module configured to perform one or more tinnitus evaluation tests. A tinnitus evaluation test may comprise generating a first single-frequency sound based at least in part on a sound of a patient's tinnitus, and generating a narrow-band sound centered at the frequency of the first single-frequency sound. Tests include a hearing threshold test, a loudness match test, a pitch match test, a bandwidth match test, a minimum masking level test, and a residual inhibition test.

Abstract: Methods for detecting an infection with Mycobacterium tuberculosis (Mtb) in a subject are disclosed. The methods include detecting the presence of CD8+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8+ T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods can also include detecting Mtb polypeptides and polynucleotides. Reagents for the detection of an Mtb infection are also disclosed.

Abstract: Methods, articles of manufacture, and systems for evaluating tinnitus are disclosed herein. According to various embodiments, a tinnitus evaluation system may include a tinnitus evaluation module configured to perform one or more tinnitus evaluation tests. A tinnitus evaluation test may comprise generating a first single-frequency sound based at least in part on a sound of a patient's tinnitus, and generating a narrow-band sound centered at the frequency of the first single-frequency sound. Tests include a hearing threshold test, a loudness match test, a pitch match test, a bandwidth match test, a minimum masking level test, and a residual inhibition test.

Abstract: The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent.

Abstract: The present disclosure provides compositions and methods for on-going bowel care for persons with chronic intestinal pseudo-obstruction. The compositions and methods can be administered in a non-clinical setting. The compositions comprise acetylcholinesterase inhibitors for stimulating motility of the bowel in combination with anti-cholinergic agents to counteract the potentially dangerous cardiac side effects of the acetylcholinesterase inhibitor. In some examples, the acetylcholinesterase inhibitor, neostigmine, and the anti-cholinergic agent, glycopyrrolate, are combined in a pharmaceutical composition. Certain examples also provide the frequency and duration of administration of the disclosed drug combinations.

Abstract: A method is disclosed to identify a T cell receptor (TCR) variable (V) peptide of use as a therapeutic agent in a subject. A method is also disclosed for monitoring the efficacy of a T Cell Receptor (TCR) V peptide for the treatment of a subject. In another embodiment, a method is disclosed for selecting a TCR V peptide of use in therapy for a subject having an autoimmune disease.